Vikas Goyal, MBA, promoted to Partner to lead growth stage investments in late preclinical and clinical stage biotechnology companies. BOSTON, MASSACHUSETTS / ACCESS Newswire / May 12, 2025 / Longwood ...

LUXEMBOURG, LU / ACCESS Newswire / May 12, 2025 / Moolec Science SA (NASDAQ:MLEC; the "Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and ...

Immuno-oncology pioneer partners with AbTherx to build the next generation of immunotherapy drugs MOUNTAIN VIEW, CA / ACCESS Newswire / May 12, 2025 / AbTherx, Inc., a biotechnology company with ...

Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat complex, rare diseases while also opening new avenues for protein bioproduction ...

LUND, SE / ACCESS Newswire / May 12, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) is pleased to announce that data from its OPTIMIZE-1 clinical trial will be presented at the 2025 American ...

GOTHENBURG, SE / ACCESS Newswire / May 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB, reg. no. 556931-4692 ("IRLAB" or the "Company"), holds its Annual General Meeting ...

The global DNA sequencing services market is poised for significant expansion, with a projected valuation of USD 945.6 million in 2023, expected to surge to USD 2,080.2 million by 2033, according to ...

The global drug discovery enzymes market is poised for significant expansion, projected to grow from USD 932.4 million in 2023 to USD 1,751.3 million by 2033, advancing at a compound annual growth ...

In recent years, the landscape of dyslexia treatment has evolved dramatically. Once considered a misunderstood learning difficulty, dyslexia is now a central focus in the global movement toward ...

The global adiponectin testing market is on a significant growth trajectory, expected to expand at a CAGR of 7.9% from 2022 to 2032. With an initial valuation of USD 45.11 billion in 2022, the market ...

The global market for heat therapy units is set for remarkable expansion, driven by the increasing adoption of non-invasive pain relief solutions and a growing emphasis on rehabilitation and recovery.

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...